The Form 4 filing, a report of an insider's stock activity, was submitted on Nov. 18, 2026. The sale took place a day earlier, on Nov. 17.
Jeffrey Hessekiel serves as chief legal and administrative officer at biotechnology company Cytokinetics (CYTK).
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-17 |
| Date of Latest Transaction | 2026-11-17 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 15,106 |
| Price | $52.62 |
| Total Transaction Value | $794,877.72 |
| Insider | |
| Ticker Symbol | CYTK |
| Company | CYTOKINETICS INC |
| Insider Name | Hessekiel Jeffrey |
| Insider Title | Chief Legal & Admin Officer |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 92,837 |
| Position Size Change | 13.99% |
| Filing | |
| Filing Date | 2026-11-18 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a sale of shares, reported under SEC transaction code S. The transaction information also identifies a link to tax coverage or payment, explained below.
What was the average price of the transaction?
The average sale price was $52.62 per share for the one transaction reported in the filing.
How did this transaction affect the insider's holdings?
Jeffrey Hessekiel sold 15,106 shares and reported owning 92,837 shares afterward. The sale represented 13.99% of his reported shares owned before the sale.
What's the total transaction value?
The total transaction value was $794,877.72 for the single reported sale of 15,106 shares.
Are there any special circumstances around this transaction?
The transaction information links this sale to tax coverage or payment of an exercise price. An exercise price is what someone pays to use a stock option, a right to buy shares at a set price. The filing's footnote text was not available, so the exact purpose and payment details are unknown. The information does not establish that taxes were the only purpose.
For research purposes only; not investment advice.